Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Metagenomi says $101.7m in the bank should last into 2028 as hemophilia A editor nears clinic

The gene-editing company's latest investor deck leads with its hemophilia A candidate and a cash balance it says covers operations for roughly the next two years.

16 Nov 2026 · Metagenomi Therapeutics, Inc. MGX · Company news

Metagenomi Therapeutics has given investors a financial snapshot alongside an updated look at its pipeline, reporting $101.7 million in cash at the close of the third quarter of 2026. The company says that sum should cover its operating needs into 2028.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Metagenomi Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →